MX2023000410A - Analogos de rapamicina como inhibidores de mtor. - Google Patents

Analogos de rapamicina como inhibidores de mtor.

Info

Publication number
MX2023000410A
MX2023000410A MX2023000410A MX2023000410A MX2023000410A MX 2023000410 A MX2023000410 A MX 2023000410A MX 2023000410 A MX2023000410 A MX 2023000410A MX 2023000410 A MX2023000410 A MX 2023000410A MX 2023000410 A MX2023000410 A MX 2023000410A
Authority
MX
Mexico
Prior art keywords
rapamycin analogs
mtor inhibitors
mtor
inhibitors
rapamycin
Prior art date
Application number
MX2023000410A
Other languages
English (en)
Inventor
Gang Wang
Walter Won
Christopher Semko
Gert Kiss
Jennifer Pitzen
Nidhi Tibrewal
James Bradley Aggen
Arun P Thottumkara
Micah James Evans Gliedt
Julie Chu-Li Lee
Adrian Liam Gill
G Leslie Burnett
Original Assignee
Revolution Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revolution Medicines Inc filed Critical Revolution Medicines Inc
Publication of MX2023000410A publication Critical patent/MX2023000410A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente divulgación se refiere a análogos de rapamicina de la Fórmula general (I). Los compuestos son inhibidores de mTOR y, por lo tanto, útiles para el tratamiento de cáncer, enfermedades mediadas por el sistema inmunitario y afecciones relacionadas con la edad.
MX2023000410A 2017-05-02 2019-10-31 Analogos de rapamicina como inhibidores de mtor. MX2023000410A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762500410P 2017-05-02 2017-05-02

Publications (1)

Publication Number Publication Date
MX2023000410A true MX2023000410A (es) 2023-02-02

Family

ID=62563244

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019013031A MX2019013031A (es) 2017-05-02 2018-05-01 Análogos de rapamicina como inhibidores de mtor.
MX2023000410A MX2023000410A (es) 2017-05-02 2019-10-31 Analogos de rapamicina como inhibidores de mtor.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019013031A MX2019013031A (es) 2017-05-02 2018-05-01 Análogos de rapamicina como inhibidores de mtor.

Country Status (12)

Country Link
US (2) US20210094975A1 (es)
EP (1) EP3619216A1 (es)
JP (2) JP7348071B2 (es)
KR (1) KR20200012876A (es)
CN (1) CN110770243A (es)
AU (2) AU2018263886C1 (es)
CA (1) CA3061907A1 (es)
IL (2) IL303660A (es)
MX (2) MX2019013031A (es)
RU (1) RU2019138161A (es)
SG (1) SG11201909924VA (es)
WO (1) WO2018204416A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107073066B (zh) * 2014-09-11 2021-09-17 加利福尼亚大学董事会 mTORC1抑制剂
JP7381492B2 (ja) 2018-05-01 2023-11-15 レヴォリューション・メディスンズ，インコーポレイテッド Ｍｔｏｒ阻害剤としてのｃ２６－連結ラパマイシン類似体
AU2019262978B2 (en) * 2018-05-01 2023-07-13 Revolution Medicines, Inc. C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors
CA3103282A1 (en) * 2018-06-15 2019-12-19 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
SG11202109422WA (en) 2019-03-01 2021-09-29 Revolution Medicines Inc Bicyclic heterocyclyl compounds and uses thereof
MX2021010319A (es) 2019-03-01 2021-12-10 Revolution Medicines Inc Compuestos biciclicos de heteroarilo y usos de estos.
KR102497821B1 (ko) * 2019-08-23 2023-02-08 이화여자대학교 산학협력단 신규 mTOR 억제제 화합물 및 이의 용도
EP4055028A1 (en) 2019-11-04 2022-09-14 Revolution Medicines, Inc. Ras inhibitors
AU2020379734A1 (en) 2019-11-04 2022-05-05 Revolution Medicines, Inc. Ras inhibitors
MX2022005357A (es) 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
MX2022005525A (es) 2019-11-08 2022-06-08 Revolution Medicines Inc Compuestos de heteroarilo bicíclicos y usos de estos.
CN114980976A (zh) 2019-11-27 2022-08-30 锐新医药公司 共价ras抑制剂及其用途
IL293549A (en) 2019-12-05 2022-08-01 Anakuria Therapeutics Inc Rapamycin analogs and their uses
TW202140011A (zh) 2020-01-07 2021-11-01 美商銳新醫藥公司 Shp2抑制劑給藥和治療癌症的方法
WO2021167175A1 (ko) * 2020-02-21 2021-08-26 한국과학기술원 엠토르 신호전달 억제제를 유효성분으로 포함하는 암의 예방 또는 치료용 약제학적 조성물
CN115916194A (zh) 2020-06-18 2023-04-04 锐新医药公司 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
MX2023002248A (es) 2020-09-03 2023-05-16 Revolution Medicines Inc Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
JP2023541916A (ja) 2020-09-15 2023-10-04 レボリューション メディシンズ インコーポレイテッド がんの治療における、ｒａｓ阻害剤としてのインドール誘導体
EP4267250A1 (en) 2020-12-22 2023-11-01 Qilu Regor Therapeutics Inc. Sos1 inhibitors and uses thereof
MX2023011976A (es) * 2021-04-09 2023-11-24 Revolution Medicines Inc Sintesis de compuestos analogos de rapamicina.
KR20240017811A (ko) 2021-05-05 2024-02-08 레볼루션 메디슨즈, 인크. 암의 치료를 위한 ras 억제제
CA3217393A1 (en) 2021-05-05 2022-11-10 Elena S. Koltun Ras inhibitors
CN117500811A (zh) 2021-05-05 2024-02-02 锐新医药公司 共价ras抑制剂及其用途
EP4359417A2 (en) * 2021-06-25 2024-05-01 Apertor Pharmaceuticals, Inc. Small molecule compounds
CN114044775B (zh) * 2021-08-30 2023-04-07 杭州医学院 一种靶向泛素化诱导bcr-abl蛋白降解的化合物及其应用
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04230389A (ja) * 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
US5221740A (en) 1992-01-16 1993-06-22 American Home Products Corporation Oxepane isomers of rapamycin useful as immunosuppressive agents
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
US5741677A (en) 1995-06-07 1998-04-21 Geron Corporation Methods for measuring telomere length
AU783158B2 (en) * 1999-08-24 2005-09-29 Ariad Pharmaceuticals, Inc. 28-epirapalogs
WO2006096325A1 (en) 2005-03-07 2006-09-14 Wyeth Oxepane isomer of 42-o-(2-hydroxy)ethyl-rapamycin
SI1951724T1 (sl) 2005-11-17 2011-09-30 Osi Pharmaceuticals Llc Kondenzirani biciklični mTOR inhibitorji
MY148688A (en) 2006-08-23 2013-05-31 Kudos Pharm Ltd 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
EP1916006A1 (en) * 2006-10-19 2008-04-30 Albert Schömig Implant coated with a wax or a resin
US20080234262A1 (en) 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
WO2009131631A1 (en) 2008-04-14 2009-10-29 Poniard Pharmaceuticals, Inc. Rapamycin analogs as anti-cancer agents
CN102256966B (zh) 2008-10-17 2016-02-10 白头生物医学研究所 可溶性mTOR复合物和其调节剂
MX2011012584A (es) 2009-05-26 2012-02-21 Exelixis Inc Benzoxazepinas como inhibidores de pi3k/m tor, metodos para su uso y fabricación.
JP2014521725A (ja) 2011-08-10 2014-08-28 ノバルティス・ファルマ・アクチェンゲゼルシャフト ＪＡＫＰＩ３Ｋ／ｍＴＯＲ併用療法
CA2863243A1 (en) * 2012-11-30 2014-06-05 Hangzhou Zylox Pharma Co., Ltd. Rafamycin analogs and methods for making same
IL290330B2 (en) 2013-12-19 2023-09-01 Seagen Inc Methylene carbamate binders for use with drug-targeting conjugates
CN105461738B (zh) * 2014-06-03 2019-03-08 中国人民解放军军事医学科学院毒物药物研究所 一种雷帕霉素衍生物、其制备方法、其药物组合物及用途
KR101668590B1 (ko) * 2014-06-19 2016-10-25 전남대학교병원 재협착 억제 및 재내피화 촉진을 위한 신규한 펩타이드 화합물 및 이의 제조방법
CN107073066B (zh) * 2014-09-11 2021-09-17 加利福尼亚大学董事会 mTORC1抑制剂
EP3234607B1 (en) * 2014-12-17 2021-04-28 Siemens Healthcare Diagnostics Inc. Sandwich assay design for small molecules
WO2017044720A1 (en) * 2015-09-11 2017-03-16 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof

Also Published As

Publication number Publication date
WO2018204416A1 (en) 2018-11-08
AU2018263886A1 (en) 2019-11-28
SG11201909924VA (en) 2019-11-28
IL270333A (es) 2019-12-31
IL270333B1 (en) 2023-07-01
EP3619216A1 (en) 2020-03-11
JP2023103387A (ja) 2023-07-26
CA3061907A1 (en) 2018-11-08
RU2019138161A3 (es) 2021-08-13
AU2022268372A1 (en) 2022-12-15
IL303660A (en) 2023-08-01
US20210094975A1 (en) 2021-04-01
RU2019138161A (ru) 2021-06-02
US20230093861A1 (en) 2023-03-30
JP7348071B2 (ja) 2023-09-20
AU2018263886B2 (en) 2022-08-11
JP2020518632A (ja) 2020-06-25
KR20200012876A (ko) 2020-02-05
IL270333B2 (en) 2023-11-01
CN110770243A (zh) 2020-02-07
MX2019013031A (es) 2020-08-03
AU2018263886C1 (en) 2022-12-22

Similar Documents

Publication Publication Date Title
MX2023000410A (es) Analogos de rapamicina como inhibidores de mtor.
MX2023000081A (es) Analogos de rapamicina ligados a c40, c28 y c-32 como inhibidores de mtor.
MX2023007581A (es) Analogos de rapamicina unidos a c26 como inhibidores de mtor.
PH12018501268A1 (en) Compounds useful as kinase inhibitors
MX2020001235A (es) Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona.
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
MY202022A (en) Pyrrolotriazine compounds as tam inhibitors
SG10201811384TA (en) Mnk inhibitors and methods related thereto
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
EA201592199A1 (ru) Производные бипиразола в качестве ингибиторов jak
PH12015502018A1 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
EA201591753A1 (ru) 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh
EA201692114A1 (ru) Замещенные дигидроизохинолиноновые соединения
EA201990833A1 (ru) Соединение пиридина
MX343561B (es) Compuestos de imidazolpiridazina.
MX359032B (es) Inhibidores de pirrolopirazina cinasa.
EA201591296A1 (ru) Фталазиноны и изохинолиноны в качестве ингибиторов rock
MD20160017A2 (ro) Polimorf al inhibitorilor SYK
MX352928B (es) Compuestos de piridazina-amida.
MX342310B (es) Compuestos de tiazolopirimidina.
MY197440A (en) Heteroamatic compounds as btk inhibitors
MX2016007128A (es) Compuestos del receptor 6 de quimiocina (ccr6).
NZ711192A (en) Process for making benzoxazepin compounds
MX349548B (es) Compuestos de tienopirimidina.